Year‐wise analysis demonstrated a decreasing trend in HBV prevalence (54.5% in 2013 to 42% in 2022); a relatively stable trend in HCV (8.7% in 2013 to 8.8% in 2022, with a slight increasing trend in the middle years) and increasing trend of NAFLD (0.9% in 2013 to 14.4% in 2022), anti‐HBc (total) or occult HBV (2.8% in 2013 to 6.4% in 2022), and AIH (0.5% in 2013 to 1.8% in 2022) (Table 2 and Figure 2 ).
← all excerpts
Changing Landscape of Chronic Liver Diseases in a Tertiary Level Hospital of Bangladesh Over the Last 10 Years.
1
—
—